Friday, April 5, 2013
Trimel Pharmaceuticals Corp., of Toronto, amended its preliminary short form prospectus with details related to changes to a previously announced proposed marketed offering of stock units consisting of one share of common stock and a warrant to purchase one half share.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.